DC Circ. Boosts Teva In Row With FDA Over Merck Drugs
In a ruling Tuesday, the U.S. Court of Appeals for the District of Columbia Circuit overturned a lower court's decision that Teva had forfeited its exclusivity rights, agreeing with Teva that it should be entitled to the six-month period.
The case marks...
To view the full article, register now.